Investments Opinions The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. By EQUITY INSIDER Jul 15, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. By EQUITY INSIDER Jul 15, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It By EQUITY INSIDER Jul 7, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It By EQUITY INSIDER Jul 7, 2026 Issued on behalf of Conexeu Sciences Inc.
Personnel Announcements Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower By American News Group Jun 16, 2026 Issued on behalf of Conexeu Sciences Inc.
Personnel Announcements Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower By American News Group Jun 16, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts By EQUITY INSIDER Jun 2, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts By EQUITY INSIDER Jun 2, 2026 Issued on behalf of Conexeu Sciences Inc.
